Hydrochlorothiazide is a thiazide-type diuretic which has been used clinically for more than half a century. The drug has been widely used to treat hypertension globally and is relatively very safe. Hydrochlorothiazide acts on the distal convoluted tubules and inhibits the sodium chloride co-transporter system. This action leads to a diuretic action and loss of potassium in the urine. The half-life of hydrochlorothiazide varies from 6 to 12 hours. Of the thiazide diuretics, hydrochlorothiazide is the most frequently used for the treatment of hypertension. Unfortunately, over the past decade, the use of hydrochlorothiazide has been declining, and it is being replaced by the angiotensin-converting enzyme inhibitors, which overall are far more effective and have fewer adverse effects.
There have been countless studies showing that when hydrochlorothiazide is prescribed at doses of 12.5 mg to 25 mg per day, it can lower the systolic blood pressure by 5 mmHg to 7 mmHg and the diastolic blood pressure by 4 mmHg to 5 mmHg over a 24 hour period. While this magnitude of blood pressure lowering is small compared to the angiotensin-converting enzyme inhibitors, calcium channel blockers or beta blockers, the effects of hydrochlorothiazide are more consistent and reliable in almost all populations. At doses of 50 mg, the effects of hydrochlorothiazide are similar to those seen by calcium channel blockers (verapamil), beta-blockers (metoprolol) or angiotensin-converting enzyme inhibitors (enalapril). 
Reducing Risk of Cardiovascular disease
While hydrochlorothiazide is an effective diuretic and does lower blood pressure, the question that has been asked for decades is whether the drug also lowers the risk of cardiovascular disease, like the angiotensin-converting enzyme inhibitors. Several studies have compared the cardiovascular risk reduction for hydrochlorothiazide to the calcium channel blockers and angiotensin-converting enzyme inhibitors. Overall almost all studies show that hydrochloride is not as effective as the ACE inhibitors in reducing harm from cardiovascular disease. In fact, other studies show that while hydrochlorothiazide can lower blood pressure, it doesn't always reduce the left ventricular hypertrophy in patients with hypertension. When compared to the calcium channel blockers, some studies indicate that the use of hydrochlorothiazide is associated with a higher risk of adverse cardiovascular events for any given lowering of systolic blood pressure. 
Why hydrochlorothiazide does not lower cardiovascular harm while decreasing blood pressure is not known, but laboratory studies suggest that the drug may not be as effective as the other agents in decreasing platelet aggregation or vascular relaxation.
Despite the above concerns, hydrochlorothiazide is still the drug of choice for the treatment of hypertension in many patients. The drug is versatile and can be combined with many other antihypertensive agents without inducing interactions. The drug is easy to administer and dose. The once a day dosing also ensures that patients will remain compliant with therapy in the long run.
Hydrochlorothiazide inhibits sodium chloride transport in the distal convoluted tubule. More sodium is then excreted in the kidney with accompanying fluid. Pharmacological effects begin in about 2 hours after an oral dose, peaks in 4 hours, and lasts for about 6 to 12 hours. Hydrochlorothiazide is not metabolized, and a majority is excreted in the urine unchanged. It also causes a loss of potassium and bicarbonate.
The long-term actions of hydrochlorothiazide when it comes to reduction in blood pressure is not well understood. When administered acutely the drug does lower blood pressure by promoting diuresis and decreasing plasma volume. However, following chronic use hydrochlorothiazide appears to be reducing blood pressure by decreasing peripheral resistance. How the drug causes vasodilation is not known, but laboratory evidence suggests that it may be inhibiting the enzyme carbonic anhydrase, desensitizing the smooth muscle receptors to the rise in calcium or preventing autoregulation in the kidneys.
Dosage is 25 mg to 100 mg per day orally for edema and 25 to 50 mg per day orally for hypertension.
All the following adverse reactions have been reported:
The more serious adverse reactions are:
Hydrochlorothiazide is contraindicated in all of the following conditions:
In pregnancy, the drug is a category B drug. It can be used in pregnancy when edema has a pathological cause as those listed in the indications.
Hydrochlorothiazide is excreted in breast milk but appears to be safe for use during lactation. 
Toxicity results in dehydration and electrolyte deficiencies such as hypokalemia, hypochloremia, and hyponatremia. This occurs because of excessive diuresis. Treatment is supportive such as fluids and electrolyte replacement. If the patient becomes hypotensive, vasopressors can be used.
Healthcare workers who prescribe HCTZ should be aware of its side effects. While the drug is relatively safe, the patient's electrolyte status has to be monitored regularly. Even though hydrochlorothiazide has been the most widely used thiazide drug for hypertension, more recent evidence indicates that it may not be as effective as some of the other thiazide diuretics. Recent clinical studies indicate that both indapamide and chlorthalidone may be more effective at lowering blood pressure and reducing cardiovascular events, independent of their ability to lower blood pressure. The onus is now on healthcare workers to change their old hydrochlorothiazide prescribing habits and focus more on evidence-based treatment.
|||Núñez-Acevedo B,Domínguez-Ortega J,Rodríguez-Jiménez B,Kindelan-Recarte C,Pérez-Fernández MA, [Severe and rare adverse reaction to hydrochlorothiazide]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993). 2018 Oct-Dec; [PubMed PMID: 30602216]|
|||Akbari P,Khorasani-Zadeh A, Thiazide Diuretics 2018 Jan; [PubMed PMID: 30422513]|
|||Heymann WR, The Expanding Saga of Hydrochlorothiazide and Skin Cancer. Journal of the American Academy of Dermatology. 2018 Dec 7; [PubMed PMID: 30529707]|
|||Dhayat NA,Faller N,Bonny O,Mohebbi N,Ritter A,Pellegrini L,Bedino G,Schönholzer C,Venzin RM,Hüsler C,Koneth I,Del Giorno R,Gabutti L,Amico P,Mayr M,Odermatt U,Buchkremer F,Ernandez T,Stoermann-Chopard C,Teta D,Rintelen F,Roumet M,Irincheeva I,Trelle S,Tamò L,Roth B,Vogt B,Fuster DG, Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial. BMC nephrology. 2018 Dec 10; [PubMed PMID: 30526528]|
|||Peng X,Zhao B,Zhang L,Jiang L,Yuan T,Wang Y,Wang H,Ma J,Li N,Zheng K,Nie M,Li X,Xing X,Chen L, Hydrochlorothiazide Test as a Tool in the Diagnosis of Gitelman Syndrome in Chinese Patients. Frontiers in endocrinology. 2018; [PubMed PMID: 30319542]|
|||Roush GC,Abdelfattah R,Song S,Ernst ME,Sica DA,Kostis JB, Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis. Journal of clinical hypertension (Greenwich, Conn.). 2018 Oct; [PubMed PMID: 30251403]|
|||Musini VM,Nazer M,Bassett K,Wright JM, Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. The Cochrane database of systematic reviews. 2014 May 29 [PubMed PMID: 24869750]|
|||Roush GC,Holford TR,Guddati AK, Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension (Dallas, Tex. : 1979). 2012 Jun [PubMed PMID: 22526259]|
|||Sica DA,Carter B,Cushman W,Hamm L, Thiazide and loop diuretics. Journal of clinical hypertension (Greenwich, Conn.). 2011 Sep [PubMed PMID: 21896142]|
|||Sinha AD,Agarwal R, Thiazide Diuretics in Chronic Kidney Disease. Current hypertension reports. 2015 Mar [PubMed PMID: 25749608]|
|||Michaelis TC,Sontheimer RD,Lowe GC, An update in drug-induced subacute cutaneous lupus erythematosus. Dermatology online journal. 2017 Mar 15; [PubMed PMID: 28329511]|
|||Lee GC,Tam CP,Danesh-Meyer HV,Myers JS,Katz LJ, Bilateral angle closure glaucoma induced by sulphonamide-derived medications. Clinical [PubMed PMID: 17300572]|
|||Geanon JD,Perkins TW, Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide. Archives of ophthalmology (Chicago, Ill. : 1960). 1995 Oct; [PubMed PMID: 7575249]|
|||Karnes JH,Gong Y,Arwood MJ,Gums JG,Hall KL,Limacher MC,Johnson JA,Cooper-DeHoff RM, Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes research and clinical practice. 2014 Jun [PubMed PMID: 24794890]|
|||Price AL,Lingvay I,Szczepaniak EW,Wiebel J,Victor RG,Szczepaniak LS, The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetology & metabolic syndrome. 2013 Jul 9 [PubMed PMID: 23837919]|
|||Hydrochlorothiazide . 2006 [PubMed PMID: 30000024]|
|||Arinzon Z,Alexander P,Berner Y, Hydrochlorothiazide induced hepato-cholestatic liver injury. Age and ageing. 2004 Sep [PubMed PMID: 15271638]|